Compare NWE & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWE | FOLD |
|---|---|---|
| Founded | 1923 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.5B |
| IPO Year | 2023 | 2006 |
| Metric | NWE | FOLD |
|---|---|---|
| Price | $66.45 | $14.43 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $60.83 | $27.25 |
| AVG Volume (30 Days) | 390.8K | ★ 2.9M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.06% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ 2.94 | N/A |
| Revenue | ★ $1,610,559,000.00 | N/A |
| Revenue This Year | $4.93 | $20.50 |
| Revenue Next Year | $4.91 | $18.59 |
| P/E Ratio | $22.39 | ★ N/A |
| Revenue Growth | ★ 6.38 | N/A |
| 52 Week Low | $50.46 | $5.66 |
| 52 Week High | $72.21 | $14.46 |
| Indicator | NWE | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 47.89 | 72.08 |
| Support Level | $65.84 | $14.21 |
| Resistance Level | $68.58 | N/A |
| Average True Range (ATR) | 1.59 | 0.02 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 57.85 | 88.89 |
NorthWestern Energy Group Inc provides electricity and natural gas services in the Upper Midwest and Northwest of the U.S. in the states of Montana, South Dakota, Nebraska, and Yellowstone National Park. The company's primary segments include Electric, which includes the generation, purchase, transmission, and distribution of electricity, and Natural Gas, which includes the production, purchase, transmission, storage, and distribution of natural gas. It uses thermal, wind, hydro, or renewable energy in varying quantities, depending on the location of the facilities, to generate power. The company derives the majority of its revenue from the Electric segment.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.